JWH-015

JWH-015
(IUPAC) ime
	(2-Metil-1-propil-1H-indol-3-il)-1-naftalenilmetanon
Klinički podaci
Identifikatori
CAS broj	155471-08-2
ATC kod	nije dodeljen
PubChem	4273754
Hemijski podaci
Formula	C23H21NO
Mol. masa	327,43 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C23H21NO/c1-3-15-24-16(2)22(20-12-6-7-14-21(20)24)23(25)19-13-8-10-17-9-4-5-11-18(17)19/h4-14H,3,15H2,1-2H3 ; Key: LJSBBBWQTLXQEN-UHFFFAOYSA-N
Farmakoinformacioni podaci
Trudnoća	?
Pravni status	Legal

JWH-015 je jedinjenje iz naftoilindolne familije koje deluje kao selektivni kanabinoidni agonist. Njegov afinitet za CB₂ receptor je 13,8 nM, dok je njegov afinitet za CB₁ 383 nM, tako da se skoro 28 puta jače vezuje za CB₂ nego CB₁.^[3] JWH-015 manifestuje slabu CB₁ aktivnost, i nije selektivan u istoj meri kao JWH-133.^[4] On ima imunomodulatorno dejstvo,^[5]^[6] i CB₂ agonisti potencijalno mogu da budu korisni u tretmanu bola i inflamacije.^[7]^[8]

Reference[uredi | uredi kod]

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Aung MM, Griffin G, Huffman JW, Wu MJ, Keel C, Yang B, Showalter VM, Abood ME, Martin BR. Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB₁ and CB₂ receptor binding. Drug and Alcohol Dependence 2000; 60:133-140.
↑ Marriott KS, Huffman JW (2008). „Recent advances in the development of selective ligands for the cannabinoid CB(2) receptor”. Current Topics in Medicinal Chemistry 8 (3): 187–204. DOI:10.2174/156802608783498014. PMID 18289088.
↑ Ghosh S, Preet A, Groopman JE, Ganju RK (2006). „Cannabinoid receptor CB2 modulates the CXCL12/CXCR4-mediated chemotaxis of T lymphocytes”. Molecular immunology 43 (14): 2169–79. DOI:10.1016/j.molimm.2006.01.005. PMID 16503355.
↑ Montecucco F, Burger F, Mach F, Steffens S (2008). „CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways”. American journal of physiology. Heart and circulatory physiology 294 (3): H1145–55. DOI:10.1152/ajpheart.01328.2007. PMID 18178718.
↑ Ehrhart J, Obregon D, Mori T, Hou H, Sun N, Bai Y, Klein T, Fernandez F i dr.. (2005). „Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation”. Journal of neuroinflammation 2: 29. DOI:10.1186/1742-2094-2-29. PMC 1352348. PMID 16343349.
↑ Romero-Sandoval A, Eisenach JC (2007). „Spinal cannabinoid receptor type 2 activation reduces hypersensitivity and spinal cord glial activation after paw incision”. Anesthesiology 106 (4): 787–94. DOI:10.1097/01.anes.0000264765.33673.6c. PMID 17413917.

Spoljašnje veze[uredi | uredi kod]

	Portal Medicina
	Portal Hemija

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Aung MM, Griffin G, Huffman JW, Wu MJ, Keel C, Yang B, Showalter VM, Abood ME, Martin BR. Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB₁ and CB₂ receptor binding. Drug and Alcohol Dependence 2000; 60:133-140.

[4] Marriott KS, Huffman JW (2008). „Recent advances in the development of selective ligands for the cannabinoid CB(2) receptor”. Current Topics in Medicinal Chemistry 8 (3): 187–204. DOI:10.2174/156802608783498014. PMID 18289088.

[5] Ghosh S, Preet A, Groopman JE, Ganju RK (2006). „Cannabinoid receptor CB2 modulates the CXCL12/CXCR4-mediated chemotaxis of T lymphocytes”. Molecular immunology 43 (14): 2169–79. DOI:10.1016/j.molimm.2006.01.005. PMID 16503355.

[6] Montecucco F, Burger F, Mach F, Steffens S (2008). „CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways”. American journal of physiology. Heart and circulatory physiology 294 (3): H1145–55. DOI:10.1152/ajpheart.01328.2007. PMID 18178718.

[7] Ehrhart J, Obregon D, Mori T, Hou H, Sun N, Bai Y, Klein T, Fernandez F i dr.. (2005). „Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation”. Journal of neuroinflammation 2: 29. DOI:10.1186/1742-2094-2-29. PMC 1352348. PMID 16343349.

[8] Romero-Sandoval A, Eisenach JC (2007). „Spinal cannabinoid receptor type 2 activation reduces hypersensitivity and spinal cord glial activation after paw incision”. Anesthesiology 106 (4): 787–94. DOI:10.1097/01.anes.0000264765.33673.6c. PMID 17413917.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

JWH-015

Reference[uredi | uredi kod]

Spoljašnje veze[uredi | uredi kod]

Navigacija

Pretraga